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Retinoids Bias Integrin Expression and Function in
Cutaneous T-Cell Lymphoma
Lei Wang1, Sebastian S. DeMarco1, JianMing Chen1, Charles M. Phillips2 and Lance C. Bridges1,3
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of malignancies characterized by accumulation of
malignant T-cells within the skin. Retinoids, metabolic derivatives, and synthetic analogs of vitamin A embody an
effective CTCL therapy with over three decades of clinical use. The established mechanism of action is induction
of growth arrest and apoptosis. However, the natural role of retinoids in T-cell biology is imprinting gut-homing
properties by inducing integrin α4β7 expression. How the natural role of retinoids relates to therapeutic
effectiveness in CTCL has not been addressed and merits investigation. Here we provide evidence that retinoids,
including Bexarotene, selectively induce CTCL lineages to increase integrin β7 expression and function prior to
growth arrest and apoptosis. Interestingly, augmented CTCL cell adhesion obtained with retinoid exposure was
potently attenuated by 1,25-dihydroxyvitamin D3, a metabolic vitamin derivative involved in prompting immune
cell skin homing. The integrin-dependent adhesion changes in CTCL cells occurred through synergistic
activation of RAR and RXR nuclear receptors. These data explore the early cellular changes induced by retinoids
that may be pivotal to sensitizing CTCL cells to growth arrest and apoptosis.
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INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group
of non-Hodgkin’s lymphomas (Hwang et al., 2008). Despite
the heterologous nature of CTCL, a common hallmark of all
variants is excessive, abnormal accumulation of malignant
T-cells within the skin. Although multiple therapeutic moda-
lities exist, retinoids, natural or synthetic structural derivatives
of vitamin A, have been successfully employed for over three
decades (Zackheim, 1999). The current paradigm of action of
retinoid-based therapies is induction of apoptosis and growth
arrest (Zhang et al., 2002; Budgin et al., 2005; Nieto-
Rementeria et al., 2009). Yet, the natural role of retinoids
entails circumventing immune cell trafﬁcking and residence
within the skin niche through induction of gut-homing receptors
(Iwata et al., 2004; Mora et al., 2008; Guo et al., 2015).
How the natural role of retinoids relates or applies to
therapeutic effectiveness in CTCL has not been addressed.
The necessity of vitamin A for immune function has been
appreciated for nearly a century as Green and Mellanby
initially referred to vitamin A as an “anti-infective agent” in
1928 (Green and Mellanby, 1928; Mellanby and Green,
1929). Retinoids specify immune cell trafﬁcking to mucosa
substructures by prompting the expression of a deﬁned set of
gut-homing receptors––namely, the integrin α4β7 and the
chemokine receptor CCR9 (Mora et al., 2008; Guo et al.,
2015). Chemokine receptors and integrins function in concert
to properly disseminate immune cells by translating molecular
gradients into directed, kinetic cellular motion. Retinoids
decrease CTCL cell chemotaxis to the skin-associated chemo-
kine TARC (Richardson et al., 2007), but the contribution of
integrins in this observation has not been investigated. In
addition, it remains unknown whether CTCL cells augment
expression and function of gut-homing molecules in response
to retinoid exposure.
Retinoids elicit cellular effects through two families of
nuclear steroid receptors known as retinoic acid receptors
(RARs) and retinoid X receptors (RXRs; Sporn et al., 1994). The
RAR family traditionally pairs with RXR members to form
heterodimers. The cellular responses generated by RXR family
members are more diverse as compared with RAR activity.
Unlike the RAR family members, RXRs comprise heterodimers
that include but are not limited to thyroid hormone receptor,
liver X receptor, and peroxisome proliferator–activated
receptor-γ. Bexarotene (Targretin), a potent RXR selective
agonist, is currently the only FDA-approved retinoid for CTCL
treatment at all stages (Duvic et al., 2001a,b).
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Here we determine the cellular response that precedes
apoptosis and growth arrest in CTCL cells exposed to
retinoids. Speciﬁcally, we examined whether retinoid expo-
sure of CTCL cells altered integrin expression and function in
a manner reﬂective of the natural role of retinoids in gut
tropism. Here we provide evidence that retinoids selectively
bias CTCL cells, but not other T-cell lineages, to induce the
expression and function of the integrin β7. This response was
dependent upon the presence of a retinoid, speciﬁc for
vitamin-A derivatives, and potently inhibited with vitamin D
metabolites known to induce skin homing. Of importance,
we demonstrate that agonizing both RAR and RXR retinoid
receptors produced a synergistic adhesion response as
compared with individual receptor activation. Our ﬁndings
provide evidence for an unaddressed aspect of retinoid-based
therapies in CTCL. By occurring prior to the onset of growth
arrest and apoptosis, the functional changes in adhesion
prompted by retinoid exposure embody the earliest known
cellular response of CTCL lineages to retinoids.
RESULTS
Increased β7 expression upon retinoid exposure is a deﬁning
feature of CTCL lineages
Retinoids promote immune cell localization by governing the
integrin receptor repertoire. However, the inﬂuence retinoids
exert on integrin expression within CTCL cells is unknown.
We conducted a comprehensive analysis of migratory
β-integrin subunit expression within CTCL cells. As shown
in Figure 1, retinoids induced signiﬁcant changes in the β7
integrin subunit expression pattern in the CTCL cell lines––MJ,
HuT78, HuT102, and SeAx. Only MJ and HuT78 increased
integrin β1 subunit expression, whereas HuT78 also dam-
pened β2 subunit expression. The β2 subunit is critical for
T-cell skin homing and inﬁltration (Grabbe et al., 2002). MyLa
cells were the only CTCL cell lineage tested that did not alter
integrin expression upon retinoid exposure. Responsiveness
with respect to β7 expression was predominately localized to
the CTCL etiology, as retinoid exposure of other non-CTCL-
derived T-cell lines did not exhibit the same extent of changes
in β-subunit expression. Only Bexarotene treatment of the
non-CTCL lineage CCRFCEM line generated statistically
higher levels of β7 expression. The expression of cutaneous
lymphocyte associated antigen, a modiﬁed form of P-selectin
glycoprotein ligand, was also determined. Cutaneous lym-
phocyte associated antigen is a biomarker for skin-homing
T-cells and is involved in cell adhesion processes (Fuhlbrigge
et al., 1997). Although not as prominent as changes in
β7 expression patterns, cutaneous lymphocyte associated
antigen expression was signiﬁcantly reduced upon retinoid
exposure in two of the CTCL cell lines examined (Supple-
mentary Figure 1 online).
Increased β7 function is a common response of CTCL lineages
treated with retinoids
We next determined whether the retinoid-induced integrin
expression changes had a functional impact. The CTCL cell
lines demonstrated augmented adhesion to the recombinant
α4β7 gut-homing ligand mucosal addressin cell adhesion
molecule-1-Fc (MAdCAM-1-Fc) upon exposure to all-trans-
retinoic acid (ATRA) compared with vehicle (Figure 2a).
Interestingly, ATRA increased adhesion of SeAx cells without
inducing detectable levels of β7 subunit expression (Figure 1).
Even though the CCRFCEM increased expression of β7
(Figure 1), retinoid responsiveness was selective to the
CTCL-derived lines with respect to β7-dependent adhesion.
Similar results were obtained when CTCL cell lines were
cultured with Bexarotene (Figure 2b).
As we included MnCl2 in our adhesion buffer as a pan-
integrin activator, we determined whether the function of β7
speciﬁcally contributed to the observed results. These
experiements employed vascular cell adhesion molecule
(VCAM)-1, a trafﬁcking ligand capable of binding both α4β7
and α4β1 (Postigo et al., 1993). The identity of the integrin
facilitating the augmented adhesion reported was conﬁrmed
by employing the anti-β7 activating mAb, 2G3 (Figure 2c;
Byron et al., 2009). Upon selective β7 integrin activation,
statistically higher levels of cell adhesion were obtained with
the retinoid-exposed cells in the MJ, HuT78, and HuT102 cell
lines as compared with vehicle-treated cells. SeAx and MyLa
cells failed to induce detectable adhesion with 2G3 to
VCAM-1. As β1 subunit expression increased in HuT78 and
MJ cell lines upon retinoid treatment (Figure 1), we also
assessed β1 function in these particular lines by utilizing the
anti-β1 activating mAb, QE2E5. Retinoid exposure increased
β1-dependent adhesion to VCAM-1 in these cell lines
(Supplementary Figure 2a online). Inhibitory antibodies and
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Figure 1. Retinoids selectively induce integrin expression in cutaneous T-cell lymphoma (CTCL) cell lines. Indicated T-cell lines were cultured for 72 hours in
the presence of 100 nM all-trans-retinoic acid (ATRA; gray), 1 μM Bexarotene (black), or equimolar concentration of the vehicle DMSO (white). Cells were
harvested and assessed for integrin β-subunit expression.
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control IgG experiments in select cell lines conﬁrmed our
ﬁndings (Supplementary Figure 2b,c online). These data
demonstrate that CTCL cells respond to retinoids in a manner
akin to the natural immune trafﬁcking properties of vitamin-A
derivatives.
Retinoid exposure augments CCL25-mediated activation of the
β7 integrin subunit
Adhesion experiments shown in Figure 2 included MnCl2 to
uniformly activate integrin receptors or antibodies to selec-
tively activate particular β-subunits. Activation was obligate
for heightened adhesion levels on MAdCAM-1-Fc, suggesting
that retinoid stimulation does not activate integrins in CTCL
cells (Figure 2d). MnCl2 and activating antibodies are exogen-
ous manipulations, and we wanted to determine whether a
physiologically relevant stimulus would replicate our ﬁndings.
Recognition of CCL25 induces β7-dependent adhesion to
immobilized MAdCAM and induces T-cell recruitment
(Eksteen et al., 2004). We demonstrate that retinoids induce
binding of MAdCAM-1-Fc in solution to the cell surface of
HuT78 without prior activation (Figure 3a). Importantly, CCL25
stimulation further enhanced binding of soluble MAdCAM-1-Fc
to the cell surface of HuT78 exposed to retinoids (Figure 3b).
Similar results were obtained with MJ cells (Supplementary
Figure 3 online). Our data indicate that retinoids predispose
and sensitize CTCL cells to endogenous integrin activating
molecules such as chemokines to promote β7-mediated
function.
The presence of vitamin-A derivatives is required for increased
β7 function
Both physiological and pharmacological levels of retinoids
induced adhesion, and the extent of CTCL cell adhesion
increased with retinoid concentration (Figure 4a). Plasticity
with respect to retinoid exposure has been previously
reported for primary and immortal immune cells (Mora
et al., 2008). We demonstrate that augmented CTCL cell
adhesion also required the presence of the retinoid. Within
72–96 hours of retinoid removal, cell adhesion returned to
levels obtained with vehicle-treated cells (Figure 4b). We also
determined whether CTCL cells differentially respond to
physiological isomers of retinoic acid. As shown in
Figure 4c, the three predominate isomers ATRA, 13-cis-RA,
and 9-cis-RA all induced adhesion to MAdCAM-1-Fc. The
CTCL cell response was selective for retinoids as the
dihydroxy form of vitamin D3, 1,25(OH)2D3, which facilitates
that immune localization to the skin did not generate
increased levels of adhesion. Vitamin K2 was utilized as a
control as it is fat soluble similar to vitamin A and D but has
not been implicated in immune cell trafﬁcking.
The vitamin D3 metabolite, 1,25(OH)2D3, inhibits retinoid-
induced CTCL cell adhesion
Although 1,25(OH)2D3 did not prompt adhesion of CTCL
cells (Figure 4c), it prevents retinoic acid–induced β7
expression within naive T-cells (Sigmundsdottir et al., 2007).
However, both vitamin-A and D derivatives have proven
beneﬁcial in CTCL treatment, and a combinatorial approach
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Figure 2. Retinoids augment integrin β7 function in cutaneous T-cell lymphoma (CTCL) cell lines. (a) T-cell lines were incubated for 72 hours with DMSO or
100 nM all-trans-retinoic acid (ATRA). Adhesion to 0.75 μgml−1 of immobilized mucosal addressin cell adhesion molecule (MAdCAM)-1-Fc was determined.
Ordinate values (average A405) represent the relative extent of adhesion. Assay buffer included MnCl2 to uniformly activate integrin receptors. (b) Adhesion assays
were repeated as in a with cells exposed to 1 μM Bexarotene. (c) CTCL cells cultured for 72 hours in the presence of 100 nM ATRA (gray), 1 μM Bexarotene
(black), or vehicle (white) were added to wells coated with 0.5 μgml−1 of vascular cell adhesion molecule (VCAM)-1 in buffer containing 15 μgml−1 of the β7
activating antibody 2G3. (d) CTCL cells were cultured for 72 hours in the presence of 100 nM ATRA, 1 μM Bexarotene, or vehicle. Adhesion was the determined
on immobilized MAdCAM-1-Fc in the absence or presence of the pan-integrin activator Mn2+.
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has been proposed (Zhang and Duvic, 2006). We wanted to
determine whether the inﬂuence of vitamin A and vitamin D
on CTCL adhesion would be complementary or antagonistic.
Co-culturing CTCL cells with retinoid and 1,25(OH)2D3
potently attenuated β7-mediated cell adhesion to MAdCAM-
1-Fc (Figure 5). Inhibition was speciﬁc for 1,25(OH)2D3
activity as culturing cells with retinoid and vitamin K2 did
not signiﬁcantly lower adhesion when compared with
retinoid alone.
Retinoids elicit adhesion changes in CTCL cells by nuclear
receptor synergism
The molecular details of how retinoids inﬂuence CTCL cells
are unknown. Our data demonstrate that RAR ligands (e.g.,
ATRA) or RXR selective ligands (e.g., Bexarotene) alone are
capable of promoting β7-speciﬁc expression and function.
We sought to determine whether concomitant activation of
RARs and RXRs would be additive or synergistic. To address
how CTCL cells transduce retinoid exposure to cell adhesion,
we used an acute exposure of low doses of the well-
characterized pan RAR agonist TTNPB alone or in combina-
tion with a low dose of Bexarotene. Although RAR and RXR
activation alone resulted in a higher level of adhesion to
MAdCAM-1-Fc compared with vehicle, a synergistic adhe-
sion response was evident when the agonists were adminis-
tered together within 48 hours of exposure (Figure 6). Cell
adhesion increased greater than threefold over levels
achieved with stimulating RAR and RXR receptors individu-
ally. Similar results were also obtained with the HuT102 cell
lines (Supplementary Figure 4 online). To validate that the
synergism was not unique to Bexarotene, we also agonized
RXR receptors with another retinoid, SR11237, which yielded
the same result (Figure 6). These data provide initial resolution
as to how retinoids mechanistically induced speciﬁc cellular
changes in CTCL cells.
DISCUSSION
On the basis of seminal ﬁndings by Zhang et al., 2002, the
current mechanism of action of retinoids in CTCL intervention
entails the induction of apoptosis. The mechanism has
recently been clariﬁed to include G1 and G2/M growth
arrest (Nieto-Rementeria et al., 2009). Although experiments
presented here used similar concentrations of Bexarotene, a
deﬁning distinction between our current work and the initial
mechanistic ﬁndings of Zhang et al., 2002 and Nieto-
Rementeria et al., 2009 is exposure time. A 96-hour exposure
was required to induce growth arrest and apoptosis in all
CTCL cell lines tested, but we assessed the cellular effects
of retinoids in advance of the 96-hour time point. The
fundamental changes in integrin expression and function in
CTCL cells reported here precede apoptotic induction and the
onset of growth arrest and are therefore the earliest
characterized cellular response of CTCL lineages to retinoids.
If CTCL cells elicit an initial, natural response to retinoids
by increasing the expression and function of gut-homing
molecules (e.g., α4β7), this response may predispose the
malignant cells to growth arrest and apoptosis. Indeed, pro-
skin–homing molecules are known to be critical growth
signals for the establishment and expansion of CTCL (Hwang
et al., 2008; Wu et al., 2009). Rapidly altering the expression
and function of multiple trafﬁcking molecules could be an
obligate trigger within CTCL etiology for apoptosis. Future
work will determine whether the apoptosis and cessation of
growth initiated by retinoid exposure is contingent upon
changes in integrin receptor expression and function.
Although it is appreciated that retinoids activate the RAR
and RXR family of nuclear receptors to elicit cellular changes,
the molecular details with respect to which nuclear receptors
are required for retinoic acid action in CTCL therapy remain
unknown. Exploiting the receptor isotype combinations
speciﬁcally involved in CTCL retinoid sensitivity embodies
an unexplored therapeutic approach with great potential
for discovery. Here we delineate that CTCL cells transduce
retinoid exposure into cellular effects by RAR/RXR nuclear
receptor synergism. Because of the synergism, lowered
concentration of agents and exposure times were required.
Whether this same synergistic mechanism or pairs of nuclear
receptors account for the clinically advantageous growth
effects in CTCL merits investigation.
The clinical importance of delineating how retinoid
stimulation is transduced into cellular outcomes is cham-
pioned by the fact that the full clinical beneﬁt of Bexarotene is
unrealized because of a diverse array of metabolic side effects
associated with its use. A clinical study reported that, of 94
patients administered Bexarotene, 25% presented with
hypertriglyceridemia, 21% with hypothyroidism, and 18%
with hypercholesterolemia (Duvic et al., 2001a). Bexarotene
serum concentrations in clinical trials range from 3.1 to
17.5 μM, with the former representing levels determined at
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the current recommended dosing (Miller et al., 1997).
Although Bexarotene is attractively marketed as a highly
selective RXR agonist, the pharmacological speciﬁcity at such
high concentrations is compromised and off-target effects with
RARs and/or RXRs paired with liver X receptor and thyroid
hormone receptor likely account for the metabolic complica-
tions. At pharmacological levels, Bexarotene decreases TSH
mRNA abundance in the pituitary (Sharma et al., 2006). In
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light of the strong clinical promise of retinoids in the treatment
of CTCL, further mechanistic studies are needed in order to
develop more reﬁned therapies that curtail adverse off-target
effects.
Here we provide a framework in which retinoids selectively
induce the expression and function of gut-homing receptors in
CTCL cells. These studies provide mechanistic insight into the
biological response of CTCL cells to retinoids preceding
apoptosis. Of critical importance, the initial molecular details
with respect to nuclear receptor involvement in transducing
retinoid exposure to select CTCL cellular responses are
deﬁned. Extension of these ﬁndings will provide requisite
knowledge for increasing the speciﬁcity and efﬁcacy of
retinoid therapy in CTCL.
MATERIALS AND METHODS
Cell lines
The established human T-leukemia/lymphoma cell lines HuT78, MJ,
HuT102, Jurkat, and CCRFCEM were purchased from ATCC
(Manassas, VA). The MOLT-4 cell line was a generous gift from Dr.
Ted Bertrand (University of Alabama at Birmingham). SeAx and MyLa
lines were kindly provided by Dr Robert Gniadecki (University of
Copenhagen). All cell lines were maintained in 5% CO2 incubator
with RPMI 1640 media supplemented with 1mM sodium pyruvate,
10% (v/v) fetal bovine serum, 10mM HEPES, 1% L-glutamine, and
1% penicillin-streptomycin. SeAx and HuT102 media also contained
10Uml− 1 of recombinant IL-2.
Reagents and chemicals
Recombinant human MAdCAM-1-Fc, VCAM-1, and CCL25/TECK
were purchased from R&D Systems (Minneapolis, MN). The colori-
metric phosphatase substrate (p-nitrophenyl phosphate), vitamin-A
isomers, vitamin K2, and 1,25-(OH)2 vitamin D3, and Bexarotene
were obtained from Sigma (St Louis, MO). The RAR agonist, TTNPB,
and the RXR agonist, SR11237, were obtained from TOCRIS (Bristol,
UK) bioscience through R&D Systems. Retinoids were dissolved at
the desired concentration in DMSO and handled accordingly to
minimize light exposure.
The antibodies for expression analysis were 6S6 (anti-β1) and
TS1/18 (anti-β2), purchased from Millipore (Darmstadt, Germany).
FIB27 (anti-β7) and cutaneous lymphocyte associated antigen anti-
bodies were obtained from BD Biosciences (San Jose, CA). Function-
activating anti-integrin mAb QE2E5 (anti-β1) was afﬁnity puriﬁed
from supernatants harvested from a hybridoma cell line provided by
Dr R. Faull (Royal Adelaide Hospital, Adelaide, SA, Australia). The
anti-β7-activating mAb 2G3 was a generous gift from Dr T. Yednock
(Elan Pharmaceuticals, San Francisco, CA). Secondary goat anti-
mouse IgG FITC-conjugated mAb and goat anti-rat IgG (H+L) ﬂuor
ﬂuorescein-conjugated mAb were obtained from Millipore. The
secondary goat anti-human IgG (Fc speciﬁc) FITC-conjugated anti-
body was purchased from Caltag/Invitrogen (Carlsbad, CA).
Flow cytometry
Cells (2× 105 cells per condition) were resuspended in HEPES-
Tyrodes buffer. Cells were incubated with primary mono-
clonal antibodies against select integrin subunits for 30 minutes.
Following initial binding, cells were ﬁxed in 0.37% formalin/
1× phosphate-buffered saline (PBS), pH 7.4, for 15 minutes.
Cells were washed twice in FACS buffer (1× PBS, 2.5% (v/v)
fetal calf serum, and 0.02% (v/v) NaN3, pH 7.4) and stained
with ﬂuorescently labeled secondary antibody for 15minutes
in the dark. For analysis of mean ﬂuorescence intensity, cells were
washed, collected, and resuspended in 300 μl of FACS buffer.
Analysis was conducted with a FACS Calibur ﬂow cytometer
(Franklin Lakes, NJ) and CellQuest-Pro software (Franklin Lakes, NJ).
Cell adhesion assay
Assays were performed according to established protocols. Brieﬂy,
protein ligands were immobilized at the desired concentrations on
Immulon-2 HB microtiter wells (Thermo Scientiﬁc, Waltham, MA) in
100 μl of 0.1M NaHCO3 per well. Plates were incubated overnight at
4 °C for better equilibrium. Nonspeciﬁc adhesion was minimized by
blocking wells with 2% (w/v) BSA in HEPES-Tyrodes buffer (5 mM
HEPES, pH 7.4, 150mM NaCl, 12mM NaHCO3, 2.6 mM KCl, 0.2
mgml−1 BSA, 0.5 mM MgCl2, and 1mM CaCl2) at room temperature
for 30 minutes. Cells were cultured for the deﬁned times in the
presence of the indicated amount of retinoids, other vitamin deriva-
tives, or an equimolar concentration of vehicle (DMSO). Before
addition to wells, cells were washed twice in HEPES-Tyrodes buffer
and manually enumerated. All cell types analyzed were added
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Figure 6. Retinoids induce cutaneous T-cell lymphoma (CTCL) cell adhesion through retinoic acid receptor (RAR)/retinoid X receptor (RXR) nuclear receptor
synergism.MJ or HuT78 cells were cultured for 48 hours in the presence of vehicle, single RAR or RXR agonists, or combination of the RAR and RXR agonists. The
RAR agonist TTNPB was used at 5 nM with the RXR agonists, Bexarotene and SR11237, both being administered at 100 nM. Cell adhesion was determined on
0.75 μgml− 1 of MAdCAM-1-Fc. Absorption values were converted to adherent cells per well by using a standard curve. Signiﬁcance reﬂects combined agents
versus single agents.
L Wang et al.
Retinoids Prompt β7-Mediated Adhesion of CTCL Cells
www.jidonline.org 2107
2× 105 per well in 100 μl HEPES-Tyrodes. Cells were incubated with
ligands in the presence or absence of inhibitors or activators for 1–
2 hours at 37 °C in 5% CO2. After three consecutive washes with
HEPES-Tyrodes, wells were analyzed for bound cells by determining
the relative cellular acid phosphatase activity within each well.
Phosphatase assay buffer (1% v/v Triton X-100, 50mM sodium
acetate at pH 5.0 and 6mgml− 1 p-nitrophenyl phosphate) was
added to wells, and wells were incubated with the colorimetric
substrate for 30 minutes at 37 °C. Color was disclosed by addition
of 50 μl per well of 1 N NaOH. Absorbance values were obtained
at 405 nm. Adhesion values obtained with wells coated exclusively
with BSA were considered as background values for each experi-
mental condition and were subtracted before reporting ﬁnal
values. Adherent cells per well= adherent cells(protein ligand)–adherent
cells(BSA).
Soluble binding assay
Cells were treated with vehicle or desired concentrations of retinoids
for 72 hours. After washing, a total of 2× 105 cells per condition were
resuspended in HEPES-Tyrodes buffer. Cells were incubated with
5 μgml−1 MAdCAM-1-Fc for 30 minutes at room temperature. For
stimulation experiments, cells were incubated with 1 μgml− 1 of
CCL25 for 5 minutes, followed by 10minute incubation with
5 μgml−1 MAdCAM-1-Fc at 37 °C. Following initial binding, cells
were ﬁxed in 0.37% formalin/1× PBS, pH 7.4, for 15 minutes. Cells
were washed twice in FACS buffer (PBS, 2.5% (v/v) fetal calf serum,
and 0.02% (v/v) NaN3, pH 7.4) and stained with anti-human IgG-
FITC (Invitrogen) antibody for 15 minutes. Cells were collected and
resuspended in 300 μl of FACS buffer and analyzed using a FACS
Calibur ﬂow cytometer and CellQuest-Pro software. Values of mean
ﬂuorescence intensity represent the levels of cell adhesion to
MAdCAM-1-Fc in solution.
Statistical analyses
GraphPad Prism 6.0 software (La Jolla, CA) was used to generate
plots and statistically analyze data. Error bars represent standard
deviation values. Student t-test was utilized to establish signiﬁcance.
When appropriate for multiple comparisons, a two-way analysis of
variance with Tukey’s post hoc test was employed. Asterisks indicate
signiﬁcant changes as compared with the vehicle-treated condition
or other indicated parameter (*Po0.05, **Po0.01). Unless otherwise
indicated, results are representative of at least two independent
experiments each performed in triplicate.
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